Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

Merck announced yesterday that the US Food and Drug Administration (FDA) has approved its monoclonal antibody vaccine ...

The FDA approved the monoclonal antibody clesrovimab-cfor for the prevention of respiratory syncytial virus lower respiratory ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants ... their mothers did not receive a maternal RSV vaccine.

RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

(Reuters) -The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody ... to be protected from severe RSV — an RSV vaccine given to the mother during pregnancy or ...

The CDC’s Advisory Committee on Immunization Practices was expected to meet later in June to issue recommendations for use.

The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s been significantly impacted by the recent changes in FDA and HHS leadership.

Merck said in a release that it expects orders ... All of the companies in the market are waiting for a meeting of outside vaccine advisors to the Centers for Disease Control and Prevention ...